Angle Will Reshape Liquid Diagnostics By Capturing Circulating Tumor Cells
Following a successful fundraise, Angle is poised to further commercialize its proprietary cell-catching technology for cancer diagnosis
You may also be interested in...
The system has the potential to be the first FDA-cleared device for harvesting intact cancer cells from a blood sample for subsequent analysis.
Babson recently raised $31m to accelerate commercialization of its blood testing “ecosystem,” developed with help from Siemens Healthineers and Becton Dickinson.
MeMed’s test measures immune system response to assess a patient’s COVID-19 trajectory.